The selective phosphodiesterase 4 inhibitor, cilomilast, inhibits interleukin-8-induced pulmonary neutrophil accumulation in the rabbit Source: Eur Respir J 2001; 18: Suppl. 33, 35s Year: 2001
Inhibition of human lung fibroblast functions by roflumilast N-oxide Source: Eur Respir J 2006; 28: Suppl. 50, 662s Year: 2006
The PDE4 inhibitor roflumilast reduced bleomycin-induced pulmonary fibrotic and vascular remodeling in mice in vivo Source: Annual Congress 2008 - Animal models of pulmonary fibrosis: mechanisms and therapies Year: 2008
Roflumilast N-oxide, a selective PDE4 inhibitor, curbs platelet-leukocyte interactions Source: Annual Congress 2011 - Translational models of disease Year: 2011
Efficacy of the PDE4 inhibitor, BAY 19-8004, in a smoke-induced model of pulmonary inflammation in the guinea pig Source: Eur Respir J 2001; 18: Suppl. 33, 36s Year: 2001
Roflumilast N-oxide reduces human fibroblast function Source: Annual Congress 2007 - Miscellaneous pulmonary pharmacology Year: 2007
The JAK3 inhibitor CP-690550 is a potent anti-fibrosis agent in a murine model of pulmonary fibrosis induced by bleomycin Source: Annual Congress 2012 - Idiopathic pulmonary fibrosis Year: 2012
ONX0912, a novel proteasome inhibitor for the treatment of lung fibrosis? Source: Annual Congress 2012 - New drug targets and pre-clinical models for respiratory diseases Year: 2012
Effect of CHF6001, a novel inhaled phosphodiesterase-4 inhibitor (PDE4i) on markers of inflammation in COPD patients Source: International Congress 2019 – Advances in COPD pharmacology Year: 2019
PAR-2 antagonist inhibits bleomycin-induced lung fibrosis. Source: International Congress 2019 – Extracellular matrix formation and remodelling in physiology and disease Year: 2019
Efficacy of the selective phosphodiesterase (PDE) 4 inhibitor, BAY 19-8004, in a rat model of neutrophilic lung inflammation Source: Eur Respir J 2001; 18: Suppl. 33, 36s Year: 2001
Naftopidil, a selective a1 adrenoceptor antagonist, inhibits the growth of lung fibroblasts and attenuates bleomycin-induced lung fibrosis in mice Source: International Congress 2017 – Lung fibrosis: basic science Year: 2017
The PDE4 inhibitor roflumilast N-oxide partly reversed TGFß1-induced changes in collagen I and E-cadherin expression in human airway epithelial cells Source: Annual Congress 2008 - Novel experimental approaches to understanding asthma and COPD Year: 2008
Effects of elastase inhibitor on the epithelial cell apoptosis in bleomycin-induced pulmonary fibrosis Source: Annual Congress 2008 - Management of idiopathic pulmonary fibrosis: what can we learn from the pathophysiology? Year: 2008
The CDK4/6 inhibitor, palbociclib intensifies pulmonary inflammation in bleomycin-induced lung fibrosis Source: Virtual Congress 2020 – Novel immunopathological mechanisms of lung disease: knowledge from translational studies Year: 2020
Dose-dependent inhibitory effect of Roflumilast, a new, orally active, selective phosphodiesterase 4 inhibitor, on allergen-induced early and late asthmatic reaction Source: Eur Respir J 2002; 20: Suppl. 38, 110s Year: 2002
RF22c, a 5-lipoxygenase inhibitor, in monocrotaline-induced PAH Source: International Congress 2019 – Pulmonary hypertension with lung diseases and experimental pulmonary hypertension Year: 2019
Effect of PDGF receptor tyrosine kinase inhibitor AG1296 on bleomycin-induced lung fibrosis in mice Source: Annual Congress 2004 - Pulmonary fibrosis - new insights Year: 2004
Effects of CHF6297, a potent and selective p38a MAPK inhibitor, in murine models of steroid resistant lung inflammation Source: International Congress 2017 – Towards new anti-inflammatory and anti-fibrotic agents Year: 2017
Effect of a pan-JAK inhibitor pyridone 6 on airway responses in murine asthma model Source: Annual Congress 2010 - Asthma: basic science and clinical studies Year: 2010